News of Note—GlaxoSmithKline's Fluarix, CureVac and more

In this week's news of note, GlaxoSmithKline won a label expansion for Fluarix Quadrivalent. (Pixabay)

Here is some other vaccine news of note for the week:

> GlaxoSmithKline won an FDA label expansion for its Fluarix Quadrivalent. Children 6 months and older are now eligible for the flu vaccine. Release

> In its year-ahead preview at the J.P. Morgan Healthcare Conference, CureVac said it's planning phase 1 vaccine trials in rabies and seasonal flu, among its other programs. Release

> GeoVax's Ebola vaccine candidate protected 100% of macaques in a lethal challenge study. Release

> VBI Vaccines' phase 1/2a study of VBI-1901 in glioblastoma multiforme is underway as the first patient has been dosed. Release

> Novavax is planning to move from its current site in Gaithersburg, Maryland. Washington Business Journal article

Suggested Articles

The FDA is evaluating the possibility of prosecuting those involved in rogue herpes vaccine research led by a Southern Illinois University professor.

New legal complaints focus on eight Sanofi executives, most of them with local management titles, and 15 managers at distributor Zuellig Pharma.

Experts say technology is advancing to develop vaccines faster at a time of increasing emerging disease outbreaks.